Protagonist Therapeutics, Inc. [NASDAQ: PTGX] shares went lower by -2.96% from its previous closing of $8.11, now trading at the price of $7.87, also adding -0.24 points. Is PTGX stock a buy or should you stay away?
The stock had a rather active trading session with the latest closing, by far recording 958940 contracts. Compared to the average trading volume of PTGX shares, the company saw a far better performance. Moreover, the stock has a 26.02M float and a -8.85% run over in the last seven days. PTGX share price has been hovering between $16.67 and $4.47 lately, and is definitely worthy of attention.
Protagonist Therapeutics, Inc. [NASDAQ:PTGX]: Analyst Rating and Earnings
Its stock price has been found in the range of 4.47 to 16.67. This is compared to its latest closing price of $8.11.
Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Tue 10 Mar (In 96 Days).
Fundamental Analysis of Protagonist Therapeutics, Inc. [PTGX]
Now let’s turn to look at profitability: with a current Operating Margin for Protagonist Therapeutics, Inc. [PTGX] sitting at -136.68.
This company’s Return on Total Capital is -36.26, and its Return on Invested Capital has reached -36.90%. Its Return on Equity is -33.39, and its Return on Assets is -25.67. These metrics suggest that this Protagonist Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -2.39. The Enterprise Value to Sales for this firm is now -739.06. Protagonist Therapeutics, Inc. [PTGX] has a Price to Book Ratio of 1.39.
Shifting the focus to workforce efficiency, Protagonist Therapeutics, Inc. [PTGX] earns $483,203 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.36 and its Total Asset Turnover is 0.20. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 5.26 and its Current Ratio is 5.26. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Protagonist Therapeutics, Inc. [PTGX] has 27.21M shares outstanding, amounting to a total market cap of $220.67M. Its stock price has been found in the range of 4.47 to 16.67. At its current price, it has moved down by -52.79% from its 52-week high, and it has moved up 76.06% from its 52-week low.
This stock’s Relative Strength Index (RSI) is at 42.31. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Protagonist Therapeutics, Inc. [PTGX] a Reliable Buy?
Shares of Protagonist Therapeutics, Inc. [PTGX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.